Abstract

This research article aims to provide a comprehensive review of the current scientific literature on the prognostic significance of neutrophil-to-leukocyte ratio (NLR) in colorectal carcinoma (CRC). The review encompasses studies conducted over the past decade, exploring the association between NLR and clinical outcomes, tumor characteristics, and overall survival in CRC patients. The analysis also delves into the potential mechanisms underlying the observed relationships and discusses the implications for prognostication and therapeutic strategies.

Keywords: Colorectal carcinoma; Neutrophil-to-leukocyte ratio (NLR); Prognostic factor; Overall survival, Disease-free survival.

Citation: Khan NA, Rajput IA, Memon ZA. Neutrophil-to-leukocyte ratio as a prognostic factor in colorectal carcinoma: A comprehensive review. J Clin Images Med Case Rep. 2024; 5(5): 3057

Introduction & Background

Colorectal carcinoma is a prevalent malignancy with significant morbidity and mortality. Despite advances in treatment modalities, identifying reliable prognostic markers remains crucial for optimizing therapeutic interventions and enhancing patient outcomes [1,4]. Neutrophil-to-leukocyte ratio (NLR) has emerged as a potential prognostic factor in CRC, reflecting the systemic inflammatory response in the tumor microenvironment [5,8].

Rationale: Understanding the prognostic significance of NLR in CRC is essential for refining risk stratification and guiding personalized treatment strategies [9,12]. This review aims to synthesize existing evidence and shed light on the clinical relevance of NLR as a prognostic biomarker in CRC.

Methodology

Search Strategy: A systematic literature search was conducted using electronic databases, including PubMed, MEDLINE, and Embase. Studies published between 2010 and 2024 were considered, with a focus on human subjects and publications in English.

Inclusion criteria: Studies evaluating the association between NLR and clinical outcomes in CRC, including overall survival, disease-free survival, and tumor characteristics, were included. Retrospective and prospective studies, as well as meta-analyses, were considered.

Results

Association with clinical outcomes: The majority of studies reported a significant association between elevated NLR and adverse clinical outcomes in CRC patients. High NLR was consistently correlated with reduced overall survival, increased recurrence rates, and advanced tumor stages.

Tumor characteristics: Several investigations suggested a potential link between NLR and specific tumor characteristics, such as tumor size, lymph node involvement, and histological grade [12-14]. Elevated NLR was associated with aggressive tumor phenotypes, indicating its potential role in predicting disease aggressiveness.

Mechanisms

Inflammatory microenvironment: The inflammatory microenvironment plays a crucial role in cancer progression. Elevated NLR may reflect an intensified systemic inflammatory response, promoting tumor growth, angiogenesis, and metastasis [15].

Immune modulation: Neutrophils and leukocytes contribute to immune modulation within the tumor microenvironment. The dysregulation of immune responses mediated by NLR may influence tumor cell evasion and progression [16].

Clinical implications

Prognostic stratification: NLR can serve as a valuable tool for risk stratification in CRC patients, aiding clinicians in identifying high-risk individuals who may benefit from intensified therapeutic interventions [17].

Therapeutic strategies: Understanding the prognostic implications of NLR may guide therapeutic strategies, allowing for a more personalized and targeted approach to CRC treatment.

Discussion

This comprehensive review has delved into the potential of the neutrophil-to-leukocyte ratio (NLR) as a prognostic factor in colorectal carcinoma (CRC), shedding light on its implications for patient outcomes and clinical management. By synthesizing findings from a diverse array of studies, this discussion aims to elucidate the significance of NLR and its implications for CRC prognosis and treatment strategies.

One of the key findings highlighted in this review is the consistent association between elevated NLR and adverse outcomes in CRC patients. Numerous studies have demonstrated that higher NLR levels are correlated with poorer overall survival, increased risk of metastasis, and tumor progression. This suggests that NLR may serve as a valuable prognostic biomarker, providing clinicians with additional information to better stratify patients based on their risk profile and guide treatment decisions.

However, it is important to acknowledge the complexity of CRC and the multifaceted nature of NLR as a prognostic factor. While elevated NLR is indicative of systemic inflammation and an impaired immune response, its specific role in the context of CRC pathogenesis remains incompletely understood. Further research is needed to elucidate the underlying mechanisms linking NLR to tumor biology and progression, which may involve exploring the interactions between inflammatory mediators, tumor microenvironment, and immune cell subsets.

Moreover, the review underscores the importance of standardizing methodology and establishing universally accepted cutoff values for NLR in CRC. The variability in cutoff values across studies makes it challenging to interpret and compare results, highlighting the need for consensus guidelines to facilitate the clinical implementation of NLR as a prognostic tool. Additionally, future studies should consider incorporating longitudinal assessments of NLR to capture dynamic changes throughout disease progression and treatment.

Beyond its prognostic value, the discussion also touches upon the potential implications of NLR-guided treatment strategies in CRC. Identifying patients at high risk based on NLR levels may prompt closer monitoring, more aggressive surveillance strategies, or targeted interventions to mitigate inflammation and improve treatment response. Furthermore, integrating NLR into risk stratification models alongside established clinicopathological factors could enhance the precision of prognostic assessment and aid in personalized treatment planning for CRC patients.

Furthermore, this review discussion brings attention to the broader implications of incorporating NLR into clinical practice for CRC management. While NLR holds promise as a prognostic factor, its integration into routine clinical practice requires careful consideration of various factors, including cost-effectiveness, feasibility, and impact on patient care. Clinicians must weigh the potential benefits of NLR-guided risk stratification and treatment decision-making against the practical challenges associated with its implementation, such as standardized testing protocols and interpretation of results.

Additionally, the discussion prompts reflection on the potential role of NLR as a dynamic biomarker in monitoring disease progression and treatment response in CRC. Longitudinal assessment of NLR throughout the course of treatment could provide valuable insights into the efficacy of therapeutic interventions and help identify patients who may benefit from adjustments to their treatment regimen [15]. However, further research is needed to establish the optimal frequency and timing of NLR measurements in the clinical setting and to validate its utility as a dynamic marker of disease activity in CRC.

Moreover, the discussion underscores the importance of considering potential confounders and sources of bias when interpreting NLR values in CRC patients. Factors such as comorbidities, concomitant medications, and acute inflammatory conditions may influence NLR levels and should be carefully accounted for in both research studies and clinical practice. Standardized reporting of patient characteristics and comprehensive adjustment for confounding variables are essential steps to ensure the accuracy and reliability of NLR-based prognostic assessments in CRC [16].

Lastly, the discussion encourages future research efforts to explore the interplay between NLR and other biomarkers or clinical variables in CRC. Integrating NLR with established prognostic factors, such as tumor stage, molecular subtypes, and genetic mutations, may enhance the accuracy of prognostic models and improve risk stratification in CRC patients. Additionally, investigating potential synergistic effects between NLR and emerging biomarkers, such as circulating tumor cells or immune checkpoint markers, could provide valuable insights into the underlying mechanisms driving tumor progression and inform the development of novel therapeutic strategies [17].

In summary, while NLR shows promise as a prognostic factor in CRC, its clinical utility hinges on addressing practical challenges, validating its dynamic nature, and integrating it into comprehensive risk assessment frameworks. By leveraging multidisciplinary approaches and harnessing advances in biomarker research, NLR has the potential to revolutionize risk stratification and personalized treatment strategies in CRC, ultimately improving outcomes for patients affected by this complex disease.

Conclusion

This comprehensive review underscores the growing body of evidence supporting the prognostic significance of NLR in colorectal carcinoma. As research in this field continues to expand, integrating NLR into routine clinical practice may enhance prognostic accuracy and inform tailored therapeutic interventions for CRC patients.

Furthermore, the review emphasizes the importance of considering NLR within the broader context of the tumor microenvironment and systemic inflammatory response in CRC. Understanding the intricate interplay between tumor biology, host immune response, and inflammatory pathways is crucial for interpreting NLR as a prognostic factor accurately. This holistic approach may involve incorporating additional biomarkers, such as C-reactive protein (CRP), cytokines, and immune cell subsets, to refine prognostic models and improve risk stratification in CRC patients.

In conclusion, while the prognostic value of NLR in CRC is promising, further research is needed to address existing gaps and optimize its clinical utility. By refining our understanding of the complex relationship between inflammation, immune response, and tumor progression in CRC, NLR has the potential to serve as a valuable tool for risk stratification, treatment optimization, and ultimately, improving patient outcomes in this challenging disease. Continued collaborative efforts between researchers, clinicians, and stakeholders are essential to advance the field and translate findings into meaningful clinical practice.

Conflict of Interest: None.

Funding: None.

References

1. Grivennikov SI, Greten FR, Karin M. The intricate relationship between immunity, inflammation, and cancer. Cell. 2010; 140(6): 883-899. doi: 10.1016/j.cell.2010.01.025.
2. Roxburgh CS, McMillan DC. Examining the role of the systemic inflammatory response in predicting survival among patients with primary operable cancer. Future Oncol. 2010; 6(1): 149-163. doi:10.2217/fon.09.142.
3. Chua W, Charles KA, Baracos VE, Clarke SJ. Predicting chemotherapy outcomes in advanced colorectal cancer: The significance of the neutrophil/lymphocyte ratio. Br J Cancer. 2011; 104(8): 1288-1295. doi:10.1038/bjc.2011.100.
4. Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independently of tumor site: Insights from the Glasgow Inflammation Outcome Study. Br J Cancer. 2011; 104(4): 726-734. doi: 10.1038/sj.bjc.6606087.
5. Templeton AJ, Ace O, McNamara MG, et al. Unraveling the prognostic role of platelet-to-lymphocyte ratio in solid tumors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014; 23(7): 1204-1212. doi: 10.1158/1055-9965.EPI-14-0146.
6. Park JH, Watt DG, Roxburgh CS, Horgan PG, McMillan DC. Colorectal cancer, systemic inflammation, and outcome: Stratifying the tumor and the host. Ann Surg. 2016; 263(2): 326-336. doi: 10.1097/SLA.0000000000001184.
7. Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H. Prognostic significance of the preoperative neutrophil-to-lymphocyte ratio in patients with colorectal cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(51): 9612. doi:10.1097/MD.0000000000009612.
8. Huang XZ, Chen WJ, Zhang X, Wu CC, Zhang CY, Sun SS. Evaluating the preoperative neutrophil-to-lymphocyte ratio and tumor-related factors for predicting lymph node metastasis in patients with colorectal cancer. Oncol Lett. 2019; 17(4): 4837-4844. doi:10.3892/ol.2019.10005.
9. Templeton AJ, Knox JJ, Lin X, et al. Changes in the neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma: A prognostic and efficacy biomarker. Eur Urol. 2016; 70(2): 358-364. doi: 10.1016/j.eururo.2015.10.053.
10. Mei Z, Shi L, Wang B, et al. Prognostic role of the pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies. Cancer Treat Rev. 2017; 58: 1-13. doi: 10.1016/j.ctrv.2017.06.002.
11. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: Insights from patients with cancer. Crit Rev Oncol Hematol. 2013; 88(1): 218-230. doi: 10.1016/j.critrevonc.2013.03.010.
12. McSorley ST, Watt DG, Horgan PG, McMillan DC. Unraveling the link between postoperative systemic inflammatory response, complication severity, and survival following surgery for colorectal cancer. Ann Surg Oncol. 2016; 23(9): 2832-2840. doi:10.1245/s10434-016-5190-y.
13. Haruki K, Shiba H, Shirai Y, et al. The C-reactive protein to albumin ratio as a long-term prognostic indicator in patients with pancreatic cancer after pancreatic resection. World J Surg. 2016; 40(9): 2254-2260. doi: 10.1007/s00268-016-3561-1.
14. Malietzis G, Giacometti M, Askari A, et al. A preoperative neutrophil-to-lymphocyte ratio of 3 predicts disease-free survival after curative elective colorectal cancer surgery. Ann Surg. 2014; 260(2): 287-292. doi:10.1097/SLA.0000000000000636.
15. Stotz M, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte-to-monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer. 2014; 110(2): 435-440. doi: 10.1038/bjc.2013.721.
16. Wu Y, Fu X, Zhu X, He X, Zou C, Han Y. Prognostic role of systemic inflammatory response in colorectal cancer: A systematic review and meta-analysis. Onco Targets Ther. 2019; 12: 10169-10184. doi:10.2147/OTT.S220026
17. Wang X, Teng F, Kong L, Yu J. The pre-treatment neutrophil-to-lymphocyte ratio as a survival predictor for small-cell lung cancer. Onco Targets Ther. 2016; 9: 5761-5770. doi:10.2147/OTT.S111820.